Discover next-generation cell line and manufacturing methods that boost productivity, improve purity, and remove bottlenecks in bispecific antibody development.
Bispecific antibodies hold enormous therapeutic promise, but manufacturing them at high yield and high purity remains one of the toughest challenges in biologics.
In this on-demand webinar, Senior Scientist Yiting Lim reveals practical, next-generation strategies for improving bispecific antibody expression in CHO cell lines, including an antibiotic-free platform that uses only the glutamine synthetase (GS) selection marker.
You’ll also gain insights into how continuous manufacturing can streamline workflows and accelerate production of complex multi-chain molecules. Whether you’re looking to troubleshoot your current bispecific projects or modernize your approach, this session delivers actionable guidance you can put to work immediately.
Key Takeaways:
- Proven strategies for achieving higher bispecific yields and product quality
- How mRNA trans-splicing + GS-only selection simplify expression and scale-up
- Real-world results using a continuous manufacturing platform for bispecifics
- A practical blueprint for faster, cleaner, antibiotic-free bispecific production
About the Presenter
Yiting Lim, PhD, is a Senior Scientist in the Cell Line Development group at Just - Evotec Biologics in Seattle, WA.
Yiting received her PhD in Pathobiology from the Johns Hopkins University School of Medicine, completed postdoctoral research at the Fred Hutchinson Cancer Center prior to joining Just - Evotec Biologics, and has developed innovative technologies in both academia and industry.
If the video has not loaded above, please click here.
